Endometrial cancer
Conditions
Interventions
Patient receive a dose of oral dexamethasone (4 mg twice daily) from day 2 to 5 of each cycle of chemotherapy. Patient receive 16.5 mg of dexamethasone intravenously on day 1 of each week. Dose o
Sponsors
Chiba University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients aged between 20 and 75 years. 2. Patients with an Eastern Cooperative Oncology Group Performance status score 0-1. 3. Postoperative endometrial cancer patients who require chemotherapy treatment with dexamethasone. 4. Patients who have not received rdaiotherapy treatment to their pelvic region. 5. Patients who provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with diabetes mellitus who required insulin. 2. Patients who were already taking dexamethasone for osteoporosis. 3. Patients with newly diagnosed osteoporosis requiring medication. 4. T-Score: 2.5 SD or more below the young adult mean (-2.5 SD or lower). 5. Patients with a mental illness or dementia. 6. Patients with any contraindication to dexamethasone treatment. 7. Patients determined to be ineligible by the physician in charge for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the bone mineral density (BMD) variation in the lumbar vertebrae and femoral neck measured by dual energy x-ray absorptiometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in serum bone turnover markers (NTX, BAP and TRACP5b) between pre-chemotherapy and post-chemotherapy treatment. The change in glucose tolerance and insulin resistance (HOMA-R) between pre-chemotherapy and post-chemotherapy treatment. The correlation between the total amount of glucocorticoids and the change in BMD or glucose tolerance. | — |
Countries
Japan
Contacts
Public ContactAKIRA Mitsuhashi
Chiba University Hospital Gynecology
Outcome results
None listed